M&A Deal Summary |
|
|---|---|
| Date | 2013-08-02 |
| Target | Bracco - Healthcare Protective Products Division |
| Sector | Medical Products |
| Buyer(s) | Emergent BioSolutions |
| Sellers(s) | Bracco Diagnostics |
| Deal Type | Divestiture |
| Deal Value | 26M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Healthcare Services |
| Employees | 2,500 |
| Revenue | 1.1B USD (2022) |
Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 11 |
| Sector (Medical Products) | 2 of 2 |
| Type (Divestiture) | 4 of 6 |
| Country (United States) | 6 of 7 |
| Year (2013) | 1 of 1 |
| Size (of disclosed) | 5 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-06-06 |
TenX BioPharma - Monoclonal Antibody Cancer Therapy
United States TenX BioPharma - Monoclonal Antibody Cancer Therapy includes rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas. Zanolimumab has been evaluated in 130 T-cell lymphoma patients to date. Zanolimumab has received fast track and orphan drug status from the U.S. Food and Drug Administration, and orphan drug status from the European Medicines Agency. |
Buy | $6M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-02-21 |
Cangene
Winnipeg, Manitoba, Canada Cangene Corporation is a biopharmaceutical company focused on the development and commercialization of specialty therapeutics, primarily targeting biodefense applications as well as infectious disease, hematology and transplantation. |
Buy | $222M |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Medical Products |
Bracco Diagnostics, Inc. is a developer and marketer of imaging agents for use in X-ray/computed tomography, nuclear medicine, and magnetic resonance imaging.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Medical Products) | 1 of 2 |
| Type (Divestiture) | 1 of 2 |
| Country (United States) | 1 of 2 |
| Year (2013) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-04-02 |
E-Z-EM
Lake Success, New York, United States E-Z-EM, Inc. is a manufacturer of contrast agents for gastrointestinal radiology. |
Buy | $186M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-17 |
Bracco Diagnostics - Gastroenterology Business Unit
Princeton, New Jersey, United States Bracco Diagnostics, Inc. - Gastroenterology Business Unit (GBU) is a provider of CO2 insufflation systems, devices for biopsy collection and various accessories that improve the workflow and patient experience during an endoscopy procedure. |
Sell | - |
